AI assistant
GLAUKOS Corp — Director's Dealing 2015
Jun 24, 2015
31074_dirs_2015-06-24_23bbf039-0a8d-4e11-b965-0227e7570380.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: GLAUKOS Corp (GKOS)
CIK: 0001192448
Period of Report: 2015-06-24
Reporting Person: SILVERSTEIN JONATHAN (Director, 10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $7.275 | 2024-07-10 | Common Stock (10000) | Direct | |
| Series D Convertible Preferred Stock | $ | Common Stock (2406441) | Indirect | ||
| Series D Convertible Preferred Stock | $ | Common Stock (22923) | Indirect | ||
| Series E Convertible Preferred Stock | $ | Common Stock (167898) | Indirect | ||
| Series E Convertible Preferred Stock | $ | Common Stock (1599) | Indirect | ||
| Series F Convertible Preferred Stock | $ | Common Stock (280531) | Indirect | ||
| Series F Convertible Preferred Stock | $ | Common Stock (2672) | Indirect | ||
| Series D Convertible Preferred Stock Warrant (right to buy) | $ | Common Stock (27346) | Indirect | ||
| Series D Convertible Preferred Stock Warrant (right to buy) | $ | Common Stock (261) | Indirect |
Footnotes
F1: Granted July 10, 2014 pursuant to the Issuer's 2011 Stock Plan. Vests annually over a three-year period such that it is vested in full on the three-year anniversary of the grant date
F2: The shares of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock and Series F Convertible Preferred Stock shall automatically convert into shares of common stock on a 1:1 basis immediately prior to the consummation of Issuer's initial public offering ("IPO") and have no expiration date.
F3: The warrants to acquire Series D Convertible Preferred Stock shall automatically net exercise immediately prior to consummation of the IPO at the IPO price per share and the shares of Series D Convertible Preferred Stock received thereupon shall automatically convert into shares of common stock as described in footnote (2).
F4: These securities are held of record by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the sole general partner of OPI III, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP III. Samuel D. Isaly, a natural person ("Isaly"), is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP III, Advisors and Mr. Isaly may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a member of Advisors.
F5: These securities are held of record by OrbiMed Associates III, LP ("Associates III"). Advisors is the sole general partner of Associates III. Mr. Isaly is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, Advisors and Mr. Isaly may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a member of Advisors.
F6: Each of GP III, Advisors, Mr. Isaly and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.